[{"id":"ffc3eeaf-0c0b-4248-ac40-a4e3ffc99220","acronym":"","url":"https://clinicaltrials.gov/study/NCT02518113","created_at":"2021-01-18T12:10:07.428Z","updated_at":"2024-07-02T16:36:55.784Z","phase":"Phase 1b","brief_title":"A Study of LY3039478 in Combination With Dexamethasone in Participants With T-ALL/T-LBL","source_id_and_acronym":"NCT02518113","lead_sponsor":"Eli Lilly and Company","biomarkers":" NOTCH1 • FBXW7","pipe":" | ","alterations":" FBXW7 mutation • NOTCH mutation","tags":["NOTCH1 • FBXW7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FBXW7 mutation • NOTCH mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • crenigacestat (LY3039478)"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/15/2018","primary_completion_date":" 01/15/2018","study_txt":" Completion: 01/15/2018","study_completion_date":" 01/15/2018","last_update_posted":"2019-09-11"}]